Resources
25 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 5/3/2021 (updated 4/10/2024)
The U.S. Food and Drug Administration (FDA) announced on April 30, 2021 the approval of a higher dose naloxone hydrochloride nasal spray product to treat opioid overdose. The newly approved product delivers 8 milligrams (mg) of naloxone into the nasal cavity. The FDA had previously approved 2 mg and 4 mg naloxone nasal spray products.
Naloxone is a medicine that can be administered by individuals with or without medical training to help reduce opioid overdose deaths. If naloxone is administered quickly, it can counter the opioid overdose effects, usually within minutes. A higher dose of naloxone provides an additional option in the treatment of opioid overdoses.
Posted 4/26/2021 (updated 4/10/2024)
The Evidence-Based Resource Guide Series is a comprehensive set of modules with resources to improve health outcomes for people at risk for, with, or recovering from mental and/or substance use disorders. It is designed for practitioners, administrators, community leaders, and others considering an intervention for their organization or community.
Posted 3/1/2021 (updated 4/4/2024)
o CAST (calculating for an adequate system tool) produces community-specific assessments of the capacity of the components of a community substance abuse care system. CAST generates recommendations by the application of social and community determinants of health as risk coefficients to each estimate of component need. CAST can assist public health practitioners in evaluation and improvement of the capacity of community-based, substance abuse care systems.
Posted 10/21/2020 (updated 4/3/2024)
This study sought to identify best practices for retaining individuals in treatment and for achieving continuity of care between settings.
Posted 7/28/2021 (updated 4/2/2024)
The suggested tools and resources herein address the need for agencies to support frontline service providers following exposure to an overdose fatality. Frontline service providers may include any staff members that interact directly with populations that are at greater risk for experiencing overdose. The suggestions throughout the document should be implemented in keeping with agency-based policies and procedures for staff support. Introducing these strategies into the workplace can foster greater well-being among those staff members most vulnerable to trauma and distress.
The goal of these suggestions is to promote well-being in the workplace for those most vulnerable to trauma, stress and grief. To achieve this, outlined below are principles for agencies to incorporate into their organization, how to acknowledge death in the moment, approaches to coping with strong emotions, the importance of building a support system, and the process of grief.
Posted 6/30/2021 (updated 4/2/2024)
This guidance publication is intended to support the efforts of states, tribes, and local communities in addressing the needs of pregnant women with opioid use disorders and their infants and families. National data show that from 2000 to 2009 the use of opioids during pregnancy increased from 1.19 to 5.63 per 1,000 hospital births (Patrick, Schumacher, Benneyworth, Krans, McAllister, & Davis, 2012). Because of the high rate of opioid use and misuse among all women, including pregnant women, medical, social service, and judicial agencies are having to confront this concern more often and, in some communities, at alarming rates.
This guidance document provides background information on the treatment of pregnant women with opioid use disorders, summarizes key aspects of guidelines that have been adopted by professional organizations across many of the disciplines, presents a comprehensive framework to organize these efforts in communities, and provides a collaborative practice guide for community planning to improve outcomes for these families. A set of appendices provides details on implementing the recommendations in the guide as well as a summary of lessons from one community’s experience over the past decade.
Posted 10/12/2020 (updated 3/29/2024)
This update of the National Institute on Drug Abuse’s Principles of Drug Addiction Treatment is intended to address addiction to a wide variety of drugs, including nicotine, alcohol, and illicit and prescription drugs. It is designed to serve as a resource for healthcare providers, family members, and other stakeholders trying to address the myriad problems faced by patients in need of treatment for drug abuse or addiction.
Posted 9/18/2020 (updated 3/29/2024)
The National Alliance of State and Territorial AIDS Directors (NASTAD) hosted the Hepatitis A and Hepatitis B Vaccination Efforts in People Who Inject Drugs webinar last week, September 10, 2020. The session featured Centers for Disease Control and Prevention subject matter experts who discussed the epidemiology of hepatitis A and hepatitis B in people who use and inject drugs and the rationale for the vaccination recommendations. The session also featured several jurisdictions and partner organizations who shared their lessons learned and best practices for reaching and implementing vaccination services in this community.
Posted 3/19/2020 (updated 3/28/2024)
To help local leaders respond to this epidemic, USDA has worked to build infrastructure for prevention, treatment and recovery, facilitate partnerships, and drive innovation in rural communities.
Posted 1/22/2020 (updated 3/28/2024)
How Science Has Revolutionized the Understanding of Drug Addiction. PDF version of this resource is available in English and Spanish.